

Appendix Table F71. Adverse effects of pharmacological treatments for UI when compared to each other

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Chapple, 2005 ²⁵⁸	Darifenacin IR	2.5 t.i.d.	Oxybutynin IR	2.5 t.i.d.	5/8	8/8	0.6(0.4; 1.1)	-0.38 (-0.73; -0.02)
Abrams, 1998 ²²⁶	Tolterodine	2mg twice daily	Oxybutynin	5mg thrice daily	105/118	114/118	0.9 (0.9; 1.0)	-0.08 (-0.14; -0.01)
Madersbacher, 1999 ³⁴³	Propiverine	15mg thrice daily	Oxybutynin	5mg twice daily	95/149	104/145	0.9 (0.8; 1.0)	-0.08 (-0.19; 0.03)
Drutz, 1999 ²⁸³	Oxybutynin	5mg thrice a day	Tolterodine	2mg twice a day	101/112	85/109	1.2(1.0; 1.3)	0.12 (0.03; 0.22)
Lee, 2002 ³³⁵	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	94/116	62/112	1.5(1.2; 1.8)	0.26 (0.14; 0.37)
Leung, 2002 ³³⁸	Oxybutynin	5mg twice daily	Tolterodine	2mg twice daily	26/53	32/53	0.8(0.6; 1.2)	-0.11 (-0.30; 0.08)
Halaska, 2003 ³⁰²	Trospium	40mg/day	Oxybutynin	10mg/day	103/267	46/90	0.8(0.6; 1.0)	-0.13 (-0.24; -0.01)
Halaska, 2003 ³⁰²	Trospium	20mg twice daily	Oxybutynin	5mg twice daily	173/267	69/90	0.8(0.7; 1.0)	-0.12 (-0.22; -0.01)
Dmochowski, 2003 ²⁷⁸	Oxybutynin	3.9mg/day	Tolterodine LA	4mg/day	23/121	29/123	0.8(0.5; 1.3)	-0.05 (-0.15; 0.06)
Homma, 2003 ³¹¹	Oxybutynin	3mg thrice daily	Tolterodine ER	4mg/day	42/244	12/239	3.4(1.9; 6.3)	0.12 (0.07; 0.18)
Chapple, 2004 ²⁶⁵	Solifenacin	20mg once daily	Tolterodine	2mg twice daily	21/37	12/37	1.8(1.0; 3.0)	0.24 (0.02; 0.46)
Chapple, 2004 ²⁶⁵	Solifenacin	2.5mg once daily	Tolterodine	2mg twice daily	6/41	12/37	0.5(0.2; 1.1)	-0.18 (-0.36; 0.01)
Chapple, 2004 ²⁶⁵	Solifenacin	5mg once daily	Tolterodine	2mg twice daily	12/37	12/37	1.0(0.5; 1.9)	0.00 (-0.21; 0.21)
Chapple, 2004 ²⁶⁵	Solifenacin	10mg once daily	Tolterodine	2mg twice daily	12/35	12/37	1.1(0.6; 2.0)	0.02 (-0.20; 0.24)
Junemann, 2005 ³²¹	Propiverine	15mg twice daily	Tolterodine	2mg twice daily	42/100	43/101	1.0(0.7; 1.4)	-0.01 (-0.14; 0.13)

Appendix Table F71. Adverse effects of pharmacological treatments for UI when compared to each other (continued)

Reference	Active drug	Dose	Control drug	Dose	Active n/N	Control n/N	Relative risk (95% CI)	Absolute risk difference (95% CI)
Armstrong, 2007 ²³²	Oxybutynin	10mg qd	Tolterodine ER	4mg qd	404/576	254/399	1.1(1.0; 1.2)	0.06 (0.00; 0.12)
Chapple, 2007 ²⁵⁹	Tolterodine	4mg daily	Fesoterodine	8mg daily	144/290	167/288	0.9(0.7; 1.0)	-0.08 (-0.16; 0.00)
Chapple, 2007 ²⁵⁹	Tolterodine	4mg daily	Fesoterodine	4mg daily	144/290	135/272	1.0(0.8; 1.2)	0.00 (-0.08; 0.08)
Herschorn, 2010 ³⁰⁴	Solifenacin	5mg once daily	Oxybutynin IR	5mg 3 times daily	49/68	59/64	0.8(0.7; 0.9)	-0.20 (-0.33; -0.08)
Junemann, 2000 ³²⁰	Tropium	20mg twice daily	Tolterodine	2mg twice daily	26/76	25/77	1.1(0.7; 1.6)	0.02 (-0.13; 0.17)
U.S. Food and Drug Administration, ⁶⁰	Solifenacin	5mg once daily/5mg twice daily	Tolterodine ER	4mg once daily	282/593	265/607	1.1(1.0; 1.2)	0.04 (-0.02; 0.10)
NCT00444925, ⁵⁸	Fesoterodine	4 to 8mg once daily	Tolterodine ER	4 to 8mg once daily	290/685	213/690	1.4(1.2; 1.6)	0.11 (0.06; 0.17)